Background: Few data are available on the safety of COVID-19 vaccines in cancer patients undergoing active cancer-directed treatment.
Patients And Methods: This case series analyzes outcomes in terms of adverse events in 5297 patients undergoing anti-cancer treatment who were vaccinated with anti-SARS-CoV-2 Pfizer-BioNTech vaccine at a single cancer center from March 6, 2021 to May 9, 2021. Adverse events were retrieved from the national Italian pharmacovigilance platform (http://www.vigicovid.it).
Results: Of the 5297 patients treated for either solid tumors (87%) or onco-hematologic malignancies (13%) who were vaccinated, 8 adverse drug reactions (ADRs) were reported. One was a severe ADR and 7 were non-severe ADRs. Non-severe ADRs resolved within 48 hours.
Conclusion: BNT162b2 Pfizer-BioNTech vaccine was safely administered in the largest cohort of cancer patients reported to date.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895736 | PMC |
| http://dx.doi.org/10.1093/oncolo/oyab037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial.
Hum Vaccin Immunother
December 2025
Crucell Integration, Janssen Research and Development, Beerse, Belgium.
We conducted a randomized, Phase 2 trial to assess the safety and humoral immunogenicity of reduced doses/dose volume of the standard dose of Ad26.COV2.S COVID-19 vaccine (5 × 10 viral particles [vp]) in healthy adolescents aged 12-17 years.
View Article and Find Full Text PDFBeyond Food Assistance: A Scoping Review Examining Associations of Nonfood Social Safety Net Programs in the United States With Food Insecurity and Nutrition Outcomes.
Nutr Rev
January 2025
Department of Health Behavior, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Objective: To conduct a scoping review to summarize the state of the evidence on associations between participation in nonfood social safety net programs (eg, income assistance, housing assistance) in the United States and food- and nutrition insecurity-related outcomes.
Background: Food and nutrition insecurity are persistent public health challenges in the United States that increase chronic disease risk and exacerbate health disparities. Several food assistance programs enhance food and nutrition security.
Construction of an interactive humanistic nursing model in emergency rescue of epidemic outbreaks.
Pak J Med Sci
January 2025
Meijin Yuan Department of Nursing, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, Hebei, China.
Objective: To explore the clinical efficacy of the interactive humanistic nursing model in emergency rescue of epidemic outbreaks.
Methods: This was a retrospective study. A total of 200 patients with novel coronavirus pneumonia (NCP) admitted to The First Affiliated Hospital of Hebei North University between December 2022 and March 2023 were selected and divided into the observation group(n=100) and the control group(n=100) according to different nursing methods used.
Targeted barcoding of variable antibody domains and individual transcriptomes of the human B-cell repertoire using Link-Seq.
PNAS Nexus
January 2025
Institute of Bioengineering, School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
Here, we present Link-Seq, a highly efficient droplet microfluidic method for combined sequencing of antibody-encoding genes and the transcriptome of individual B cells at large scale. The method is based on 3' barcoding of the transcriptome and subsequent single-molecule PCR in droplets, which freely shift the barcode along specific gene regions, such as the antibody heavy- and light-chain genes. Using the immune repertoire of COVID-19 patients and healthy donors as a model system, we obtain up to 91.
View Article and Find Full Text PDFSafety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial.
EClinicalMedicine
January 2025
Janssen Research and Development, Beerse, Belgium.
Background: Vaccine co-administration can increase vaccination coverage. We assessed the safety, reactogenicity, and immunogenicity of concomitant administration of Ad26.COV2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!